Cullinan Associates Inc Astrazeneca PLC Transaction History

Cullinan Associates Inc

$1.4 Billion
Q1 2025

A detailed history of Cullinan Associates Inc transactions in Astrazeneca PLC stock. As of the latest transaction made, Cullinan Associates Inc holds 13,026 shares of AZN stock, worth $911,168. This represents 0.07% of its overall portfolio holdings.

Number of Shares

13,026

Previous 13,026 -0.0%

Holding current value

$911,168

Previous $853,000 12.19%

% of portfolio

0.07%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	BUY	$61.03 - $69.57 $91,422 - $104,215	1,498 Added 12.99%	13,026 $882,000
Q4 2023 Jan 24, 2024	SELL	$61.89 - $69.28 $123 - $138	-2 Reduced 0.02%	11,528 $776,000
Q3 2023 Oct 11, 2023	SELL	$64.85 - $71.7 $64 - $71	-1 Reduced 0.01%	11,530 $780,000
Q2 2023 Jul 14, 2023	BUY	$69.91 - $75.81 $25,097 - $27,215	359 Added 3.21%	11,531 $825,000
Q1 2023 Apr 05, 2023	SELL	$63.15 - $71.6 $2,273 - $2,577	-36 Reduced 0.32%	11,172 $775,000
Q4 2022 Jan 11, 2023	BUY	$54.21 - $70.44 $332,090 - $431,515	6,126 Added 120.54%	11,208 $760,000
Q3 2022 Oct 19, 2022	SELL	$53.02 - $135.75 $1.62 Million - $4.15 Million	-30,581 Reduced 85.75%	5,082 $279,000
Q2 2022 Jul 08, 2022	SELL	$59.26 - $71.14 $52,089 - $62,532	-879 Reduced 2.41%	35,663 $2.36 Million
Q1 2022 Apr 21, 2022	SELL	$55.72 - $67.12 $56,667 - $68,261	-1,017 Reduced 2.71%	36,542 $2.42 Million
Q4 2021 Jan 07, 2022	SELL	$54.02 - $63.83 $115,278 - $136,213	-2,134 Reduced 5.38%	37,559 $2.19 Million
Q3 2021 Oct 08, 2021	BUY	$55.56 - $60.79 $2.21 Million - $2.41 Million	39,693 New	39,693 $2.38 Million

Others Institutions Holding AZN

# of Institutions

1,428

Shares Held

504M

Call Options Held

10M

Put Options Held

3.14M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $217B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullinan Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cullinan Associates Inc with notifications on news.

Account

Cullinan Associates Inc Astrazeneca PLC Transaction History